Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer

Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer

Submitted by admin on January 24, 2019 - 11:43am
Source: 
CP WIre
News Tags: 
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Headline: 
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
snippet: 
  • ArQule is eligible to receive up to $326 million in regulatory and commercial milestone payments related to the BAL087 license agreement
  • BAL087 has U.S. and EU orphan drug designation
  • Urothelial cancer is the sixth most common cancer in the U.S.

Do Not Allow Advertisers to Use My Personal information